학술논문

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
Document Type
Article
Author
Thompson, George RSoriano, AlexCornely, Oliver AKullberg, Bart JanKollef, MarinVazquez, JoseHonore, Patrick MBassetti, MatteoPullman, JohnChayakulkeeree, MetheePoromanski, IvanDignani, CeciliaDas, Anita FSandison, TaylorPappas, Peter GAkova, MuratAlAgha, RawanAlangaden, GeorgeAlbrecht, Svenja JAlexander, BarbaraAl-Obaidi, MohanadAmbasch, GermanArmestar Rodriguez, FernandoAzap, AlpayBaffoe-Bonnie, AnthonyBelkhir, LeilaBen-Ami, RonenBoutoille, DavidCascio, AntonioChai, Louis YAChaiwarith, RomaneeChayakulkeeree, MetheeChen, SharonChen, Yee-ChunChen, Yen-HsuChoi, Jun YongChoi, Young HwaChotiprasitsakul, DaruneeChung, Jin WonDanion, FrançoisDenis, BlandineDiaz Santos, EmilioDictar, Miguel ODiltoer, MarcDupont, HerveFeng, SizhouFerre Colomer, Maria AngelesFerrer, RicardForel, Jean-Marie Fernand RogerFortún-Abete, JesúsGarcia-Diaz, JuliaGirardis, MassimoHe, FangHites, MayaHo, Mao-WangHonore, PatrickHorcajada Gallego, Juan PabloHuang, HaihuiHuang, Po-YenHuang, YongHussein, OsamahIntalapaporn, PojJaruratanasirikul, SutepJauregui-Peredo, LuisJohnson, MistyJung, Dong SikJutivorakool, KamonwanKern, Winfried VKett, Daniel HKhawcharoenporn, ThanaKim, Young KeunKoehler, PhilippKotanidou, AnastasiaLachiewicz, AnneLin, QinhanLopez Cortes, Luis EduardoLuo, HongLuzzati, RobertoMaor, YasminMcCarty, ToddMerelli, MariaMerino Amador, PalomaMidturi, JohnMigliorino, Guglielmo MarcoMira, Jean-PaulMootsikapun, PiroonMorrissey, OrlaMunoz Garcia de Paredes, PatriciaMussini, CristinaMylonakis, EleftheriosNseir, SaadallaNseir, WilliamOdabasi, ZekaverPapastamopoulos, VasileiosPaterson, DavidPatterson, Thomas FPeck, Kyong RanPeng, ZhiyongPermpalung, NitipongPlantefeve, Gaetan JPoromanski, Ivan GPowell, DebraPsichogiou, MinaPuah, Ser HonPullman, JohnRahav, GaliaMartinez, Antonio RamosRamos Ramos, Juan CarlosRaz-Pasteur, AyeletRestrepo Castro, Carlos ARiera, FernandoRoblot, FranceRodriguez Alvarez, Regino JoseRogers, BenjaminRoilides, EmmanuelSanchez Vallejo, GregorioSganga, GabrieleSipsas, NikolaosSlavin, MonicaSoriano, AlexSpec, AndrejStrahilevitz, JacobTancheva, Dora MTao, ZhenTeschner, DanielThompson, George RVan Wijngaerden, EricVazquez, JoseVergidis, PaschalisViale, PierluigiWang, Fu-DerWang, ShifuWeber, GabrielWeng, JianyuXu, JinfuYao, LiYavuz, SerapYilmaz, MesutYoung, Jo-AnneZarate, Abel HZeng, JunZhang, Yong
Source
The Lancet; January 2023, Vol. 401 Issue: 10370 p49-59, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystisspp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis.